© LB Pharmaceuticals., a clinical-stage biopharmaceutical company developing novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.
Christopher Zergebel serves as our Senior Vice President, Clinical Operations, bringing more than 25 years of global development operations experience across biotechnology and pharmaceutical organizations. He has deep expertise building and leading cross-functional teams across clinical operations, data management, and project and portfolio management, with a focus on aligning clinical development strategy with operational execution.
Prior to joining LB Pharmaceuticals, Mr. Zergebel served as Vice President, Development Operations at Cellectis Biologics, where he led global clinical development strategy and operations from early-stage through post-approval trials. He has held senior leadership roles responsible for establishing and optimizing development operations functions, overseeing R&D budgets, and executing clinical programs across stages of development.
Throughout his career, Mr. Zergebel has led clinical operations for programs resulting in regulatory submissions and approvals and has built global project management and clinical infrastructure capabilities. Mr. Zergebel holds a B.A. in Biology from Boston University.